Abbv stock price target

ABT Price Target | Abbott Labs Stock Forecast & Ratings See Abbott Labs price target based on 11 analysts offering 12 month price targets for Abbott Labs in the last 3 months. The average price target is $97.89 with a high forecast of $105.00 and a low forecast of $87.00. The average price target represents a 27.84% increase from the last price of $76.57. ABBV | AbbVie Inc. Analyst Estimates | MarketWatch

ABBVIE INC. : ABBV Stock Price | MarketScreener AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with AbbVie Stock Gains as Some See ‘Considerable’ Upside After ... Jun 26, 2019 · He maintained an $88 price target for the stock. Shares of AbbVie  (ticker: ABBV) went into free fall on the acquisition news, dropping 16.3% by the end of the day The stock seems unlikely to

14 brokers have issued 12 month price objectives for AbbVie's stock. Their forecasts range from $78.00 to $105.00. On average, they anticipate AbbVie's share price to reach $91.83 in the next twelve months. This suggests a possible upside of 23.7% from the stock's current price. View analysts' price targets for AbbVie.

Feb 19, 2020 Alibaba Group Holding Ltd.(NYSE:BABA): ABBV, BABA and KURE It should be noted that ABBV is a large cap (US$120b) US pharmaceutical stock so The POWR price target (using DCF) is US$166.68, representing 99%  ABBV's competitors are formidable giants. Pfizer (NYSE: PFE). A few years back, some analysts left  Feb 13, 2020 That day the Cowen set price target on the stock to $98. The stock was given Buy rating by Citigroup in its report released on September 26,  Feb 18, 2020 The consensus analyst price targets and other valuation metrics are AbbVie Inc . (NYSE: ABBV) was reiterated as Outperform and its target was raised to The stock had an $80 consensus target price and was indicated 

Top Analyst Upgrades and Downgrades: AbbVie, Biogen, Cree ...

21 hours ago · 5 out of 14 analysts covering the stock have rated it a Buy, while 7 have maintained a Hold recommendation on AbbVie Inc.. 0 analysts has assigned a Sell rating on the ABBV stock. The 12-month mean consensus price target for the company’s shares has been set at $93.77. AbbVie: Set To Retrace To Previous Highs (NYSE:ABBV ... 13 days ago · Potential Corona Virus treatment option through AbbVie's HIV drug Kaletra/Aluvia. Market conditions bringing price down to sub $70 create optimal entry for a price target of $95. Promising AbbVie's Stock Is a Bargain After Falling 8% Last Week ... AbbVie's Stock Is a Bargain After Falling 8% Last Week AbbVie's stock got walloped last week on fears the FDA could open the door to a knock-off version of Humira sooner than expected. George Budwell

Feb 06, 2020 · AbbVie stock was up 0.82% at $87.34 in morning trading on Thursday, extending Wednesday’s gains of nearly 3%, after Mizuho Securities analyst …

Abbvie Inc, ABBV:NYQ forecasts - All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions. AbbVie Inc. (ABBV) Option Chain - Stock Puts & Calls ... AbbVie Inc. (ABBV) Options Chain - Get free stock options quotes including option chains with call and put prices, viewable by expiration date, most active, and more at AbbVie Inc. Research & Ratings (ABBV) | Barron's View today's stock price, news and analysis for AbbVie Inc. (ABBV). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more.

View Price Target for ABBV Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.

See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. No. of Analysts, 7, 7, 9, 9. Avg. Estimate  Strong Buy = 5; Moderate Buy = 4; Hold = 3; Moderate Sell = 2; Strong Sell = 1. Ratings Breakdown. 3 Mths Ago. Moderate Buy. Based on 9 analysts. Created  Here again is my approach and my three stock groups: 'rebound', 'revenue' and ' virus'. Mar 18 ABBV could bounce today but there remains the risk of a deeper correction. Jan 27 AbbVie price target raised to $97 from $95 at Piper Sandler. Mar 13, 2020 Wall Street is positive on AbbVie Inc (ABBV). On average, analysts give AbbVie Inc a Buy rating. The average price target is $94.4, which  AbbVie (NYSE: ABBV) stock research, profile, news, analyst ratings, key statistics , fundamentals, Close 73.34; Price Open 75.68; Volume 2,732,591; Day's Range 74.03 - 77.26; 52 Wk Range Date, Research Firm, Action, Current, Target  AbbVie price target raised to $105 from $98 at Cowen Cowen ABBV AGN. Merck, Intel among stocks multifactor-screened for extra safety, Barron's says » 07:  Mar 17, 2020 It is also 29.93% off the consensus price target high of $106.00 offered by analysts, but current levels are 11.58% higher than the price target 

Apr 07, 2020 · Finally, Cowen upped their price target on shares of AbbVie from $98.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 18th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company. AbbVie Stock Forecast: down to 63.274 USD? - ABBV Stock ... AbbVie Inc () Stock Market infoRecommendations: Buy or sell AbbVie stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the AbbVie share forecasts, stock quote and buy / sell signals below.According to present data AbbVie's ABBV shares and potentially its market environment have been in bearish cycle last 12 months (if exists). AbbVie (NYSE:ABBV) Price Target Raised to - TechNewsObserver AbbVie (NYSE:ABBV) had its target price upped by analysts at Piper Sandler from to in a research note issued on Friday, The Fly reports. The firm currently has an “overweight” rating on the stock. Other equities analysts also recently issued reports about the company.